Aortic stenosis
Lp(a) at the crossroads: review of emerging strategies to cut residual cardiovascular risk (Curr Atheroscler Rep 2026)
Original title: Lp(a) at the Crossroads: New Strategies to Reduce Residual Cardiovascular Risk
Review of lipoprotein(a) as a genetically determined contributor to cardiovascular risk, implicated in both atherosclerotic cardiovascular disease and aortic valve stenosis. Given the high prevalence of elevated Lp(a), major cardiovascular societies now recommend at least one lifetime measurement in high-risk adults. While no approved Lp(a)-lowering therapy yet exists, several agents in advanced clinical development show considerable promise. The review outlines Lp(a)'s biological and genetic basis, its association with diverse cardiovascular diseases, and emerging therapeutic strategies that may significantly influence future clinical management of residual cardiovascular risk.
Original abstract
PURPOSE OF REVIEW: Lipoprotein(a) [Lp(a)] is an increasingly recognized, genetically determined contributor to cardiovascular risk, implicated in both atherosclerotic cardiovascular disease and aortic valve stenosis. At present, several emerging therapies specifically targeting Lp(a) are under development. RECENT FINDINGS: Given the high prevalence of elevated Lp(a) levels in the general population, major cardiovascular societies now recommend at least one lifetime measurement in all high risk adults. While no approved treatments currently exist, several novel Lp(a) lowering therapies are in advanced stages of clinical development and show considerable promise. This review outlines the biological and genetic basis of Lp(a), examines itsassociation with diverse cardiovascular diseases, and highlights emergingtherapeutic strategies that may significantly influence future clinical management.
Summary written by lp-a.org from the published abstract; figures as published. Page updated 17 August 2026. Methods.